Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Deltex Medical Group PLC - Chichester-based maker of ultrasound-based oesophageal Doppler monitoring probes - Chair Nigel Keen tells annual general meeting on Wednesday that revenue in the UK and US shows ‘encouraging signs’ of recovery from the disruption to elective surgeries caused by the Covid-19 pandemic.
‘As the number of global elective procedures increases and access into hospitals improves for our teams of clinical educators and sales experts, the use of Deltex Medical's haemodynamic monitoring technologies is expected to recover towards pre-Covid levels,’ Keen says. Meanwhile, he expects Deltex's international division to deliver ‘robust growth’ in 2022, similar to 2021.
Keen notes that access to hospitals remains a challenge for its sales people and clinical trainers. Deltex hopes the launch of its next-generation, non-invasive TrueVue monitor will help it to gain better access and to build a significant order book.
Current stock price: 1.17 pence, up 15% on Wednesday
12-month change: down 31%
Copyright 2022 Alliance News Limited. All Rights Reserved.